title: Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)
abstract: Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) and anisoylated plasminogen streptokinase activator (APSAC) in myocardial infarction has been proved to reduce mortality. A new front-loaded infusion regimen of 100 mg of rt-PA with an initial bolus dose of 15 mg followed by an infusion of 50 mg over 30 min and 35 mg over 60 min has been reported to yield higher patency rates than those achieved with standard regimens of thrombolytic treatment. The effects of this front-loaded administration of rt-PA versus those obtained with APSAC on early patency and reocclusion of infarct-related coronary arteries were investigated in a randomized multicenter trial in 421 patients with acute myocardial infarction. Coronary angiography 90 min after the start of treatment revealed a patent infarct-related artery (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3) in 84.4% of 199 patients given rt-PA versus 70.3% of 202 patients given APSAC (p = 0.0007). Early reocclusion within 24 to 48 h was documented in 10.3% of 174 patients given rt-PA versus 2.5% of 163 patients given APSAC. Late reocclusion within 21 days was observed in 2.6% of 152 patients given rt-PA versus 6.3% of 159 patients given APSAC. There were 5 in-hospital deaths (2.4%) in the rt-PA group and 17 deaths (8.1%) in the APSAC group (p = 0.0095). The reinfarction rate was 3.8% and 4.8%, respectively. Peak serum creatine kinase and left ventricular ejection fraction at follow-up angiography were essentially identical in both treatment groups. There were more bleeding complications after APSAC (45% vs. 31%, p = 0.0019).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Kliniken, Med. Klinik II, Kassel, Germany.
authors.forename: K L
authors.initials: KL
authors.lastname: Neuhaus
authors.forename: R
authors.initials: R
authors.lastname: von Essen
authors.forename: U
authors.initials: U
authors.lastname: Tebbe
authors.forename: A
authors.initials: A
authors.lastname: Vogt
authors.forename: M
authors.initials: M
authors.lastname: Roth
authors.forename: M
authors.initials: M
authors.lastname: Riess
authors.forename: W
authors.initials: W
authors.lastname: Niederer
authors.forename: F
authors.initials: F
authors.lastname: Forycki
authors.forename: A
authors.initials: A
authors.lastname: Wirtzfeld
authors.forename: W
authors.initials: W
authors.lastname: Maeurer
mesh_terms: D000328:Adult; D000368:Aged; D016255:Anistreplase / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000401:mortality; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D014654:Vascular Patency / Q000187:drug effects*
chemical_list: D016255:Anistreplase; D010959:Tissue Plasminogen Activator